bintrafusp alfa + carboplatin + nab-paclitaxel

This drug is a **combination therapy** consisting of bintrafusp alfa, carboplatin, and nab-paclitaxel, used in the treatment of various advanced solid tumors. **Bintrafusp alfa** is a bifunctional fusion protein that simultaneously targets Transforming growth factor beta (TGF-beta) and programmed death-ligand 1 (PD-L1). By blocking PD-L1, it prevents cancers from evading immune response; blocking TGF-beta disrupts tumor growth and spread, and further reactivates immune cell function. **Carboplatin** is a platinum-based chemotherapy agent that induces cell death by crosslinking DNA. **Nab-paclitaxel** is a nanoparticle albumin-bound formulation of paclitaxel (a microtubule inhibitor) for chemotherapy, with improved delivery and reduced toxicity relative to traditional formulations. This combination is evaluated in clinical trials for indications such as advanced non-small cell lung cancer, urothelial cancer, and other solid tumors[1][2][5][6].

Brand names

Abraxane (nab-paclitaxel)

Other names

albumin-bound paclitaxel (nab-paclitaxel)